A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Clinical trial NCT07226752 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07226752
- Sponsor
- Genmab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-08
- Primary completion
- 2025-10-13
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.